Top

Published in:

01-09-2020 | Lymphoma | Review Article

A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas

Authors: Daniel P. Larson, Jess F. Peterson, Grzegorz S. Nowakowski, Ellen D. McPhail

Published in: Journal of Hematopathology | Issue 3/2020

Abstract

Aggressive B-cell lymphomas, including the WHO diagnoses of diffuse large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, high-grade B-cell lymphoma, not otherwise specified, and Burkitt lymphoma, together account for approximately 40% of B-cell non-Hodgkin lymphomas. Identification of MYC, BCL2, and BCL6 rearrangements in these neoplasms is critical for diagnostic, prognostic, and therapeutic purposes. Herein, we address technical issues surrounding identification of these genetic abnormalities, discuss their diagnostic, prognostic, and therapeutic implications, and present an algorithm for use of interphase FISH in the work-up of aggressive B-cell lymphomas. To maximize sensitivity while still limiting cost, it is recommended that interphase FISH be performed in all B-cell lymphomas with large cell or high-grade morphology using both IGH/MYC dual-color dual-fusion (D-FISH) and MYC break-apart probes (BAP) as an initial probe set, followed by BCL2 BAP (or IGH/BCL2 D-FISH) and BCL6 BAP if a MYC rearrangement is identified. In pediatric patients or aggressive B-cell lymphomas with Burkitt-like morphology, a complete analysis at the outset using BAP probes for MYC, BCL2 (or IGH/BCL2 D-FISH), and BCL6 as well as D-FISH probes for IGH/MYC, IGK/MYC, and IGL/MYC is recommended.

Menon MP, Pittaluga S, Jaffe ES (2012) The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J 18(5):411–420. https://doi.org/10.1097/PPO.0b013e31826aee97CrossRefPubMedPubMedCentral

Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Espinosa I, Novelli S, Briones J, Mate JL, Salamero O, Sancho JM, Arenillas L, Serrano S, Erill N, Martinez D, Castillo P, Rovira J, Martinez A, Campo E, Colomo L, Grup per l'Estudi dels Limfomes de Catalunya i B (2013) MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 98(10):1554–1562. https://doi.org/10.3324/haematol.2013.086173CrossRefPubMedPubMedCentral

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131(18):2060–2064. https://doi.org/10.1182/blood-2017-12-820605CrossRefPubMedPubMedCentral

Paternoster SF, Brockman SR, McClure RF, Remstein ED, Kurtin PJ, Dewald GW (2002) A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol 160(6):1967–1972. https://doi.org/10.1016/s0002-9440(10)61146-7CrossRefPubMedPubMedCentral

Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, Siebert R (2006) FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 8(2):141–151. https://doi.org/10.2353/jmoldx.2006.050083CrossRefPubMedPubMedCentral

Einerson RR, Kurtin PJ, Dayharsh GA, Kimlinger TK, Remstein ED (2005) FISH is superior to PCR in detecting t(14;18)(q32;q21)–IgH/bcl-2 in follicular lymphoma using paraffin-embedded tissue samples. Am J Clin Pathol 124(3):421–429. https://doi.org/10.1309/blh8mmk85ubq4k6rCrossRefPubMed

Neat MJ, Moonim MT, Dunn RG, Geoghegan H, Foot NJ (2013) Fluorescence in situ hybridisation analysis of bone marrow trephine biopsy specimens; an additional tool in the diagnostic armoury. J Clin Pathol 66(1):54–57. https://doi.org/10.1136/jclinpath-2012-201131CrossRefPubMed

Song MK, Chung JS, Shin DY, Lim SN, Lee GW, Choi JC, Park WY, Oh SY (2017) Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy. Ann Hematol 96(1):17–23. https://doi.org/10.1007/s00277-016-2822-8CrossRefPubMed

Peterson JF, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Ketterling RP, Macon WR, Baughn LB (2019) Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. Cold Spring Harb Mol Case Stud 5(3):a004077. https://doi.org/10.1101/mcs.a004077CrossRefPubMedPubMedCentral

10.

Wagener R, Bens S, Toprak UH, Seufert J, Lopez C, Scholz I, Herbrueggen H, Oschlies I, Stilgenbauer S, Schlesner M, Klapper W, Burkhardt B, Siebert R (2019) Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma. Haematologica. 105:e202–e205. https://doi.org/10.3324/haematol.2018.208140CrossRefPubMed

11.

Muñoz-Mármol AM, Sanz C, Tapia G, Marginet R, Ariza A, Mate JL (2013) MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection. Histopathology 63(3):418–424. https://doi.org/10.1111/his.12178CrossRefPubMed

12.

King RL, McPhail ED, Meyer RG, Vasmatzis G, Pearce K, Smadbeck JB, Ketterling RP, Smoley SA, Greipp PT, Hoppman NL, Peterson JF, Baughn LB (2019) False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. Haematologica 104(6):e248–e251. https://doi.org/10.3324/haematol.2018.207290CrossRefPubMedPubMedCentral

13.

Hilton LK, Tang J, Ben-Neriah S, Alcaide M, Jiang A, Grande BM, Rushton CK, Boyle M, Meissner B, Scott DW, Morin RD (2019) The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood 134(18):1528–1532. https://doi.org/10.1182/blood.2019002600CrossRefPubMedPubMedCentral

14.

Ohno H (2006) Pathogenetic and clinical implications of non-immunoglobulin; BCL6 translocations in B-cell non-Hodgkin's lymphoma. J Clin Exp Hematop 46(2):43–53. https://doi.org/10.3960/jslrt.46.43CrossRefPubMed

15.

Kramer MHH (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92(9):3152–3162. https://doi.org/10.1182/blood.V92.9.3152CrossRefPubMed

16.

Bentley G, Palutke M, Mohamed AN (2005) Variant t(14;18) in malignant lymphoma: a report of seven cases. Cancer Genet Cytogenet 157(1):12–17. https://doi.org/10.1016/j.cancergencyto.2004.05.012CrossRefPubMed

17.

Ott G (2014) Impact of MYC on malignant behavior. Hematology Am Soc Hematol Educ Program 2014(1):100–106. https://doi.org/10.1182/asheducation-2014.1.100CrossRefPubMed

18.

Korać P, Dotlić S, Matulić M, Zajc Petranović M, Dominis M (2017) Role of MYC in B cell Lymphomagenesis. Genes 8(4):115. https://doi.org/10.3390/genes8040115CrossRefPubMedCentral

19.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele JE (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. IARC, Lyon

20.

McClure RE, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ (2005) Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29(12):1652–1660. https://doi.org/10.1097/01.pas.0000180442.87022.08CrossRefPubMed

21.

Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, Harousseau JL, Avet-Loiseau H (2007) The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92(10):1335–1342. https://doi.org/10.3324/haematol.11305CrossRefPubMed

22.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124(15):2354–2361. https://doi.org/10.1182/blood-2014-05-578963CrossRefPubMed

23.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103(11):1899–1907. https://doi.org/10.3324/haematol.2018.190157CrossRefPubMedPubMedCentral

24.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn M-H, Natkunam Y, Calaminici M, Sander B, Baia M, Smith A, Painter D, Pham L, Zhao S, Ziepert M, Jordanova ES, Molina TJ, Kersten MJ, Kimby E, Klapper W, Raemaekers J, Schmitz N, Jardin F, Stevens WBC, Hoster E, Hagenbeek A, Gribben JG, Siebert R, Gascoyne RD, Scott DW, Gaulard P, Salles G, Burton C, De Jong D, Sehn LH, Maucort-Boulch D (2019) Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol 37:3359–3368. https://doi.org/10.1200/jco.19.00743CrossRefPubMed

25.

Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28(20):3360–3365. https://doi.org/10.1200/jco.2009.26.3947CrossRefPubMed

26.

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M (2010) Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28(14):2373–2380. https://doi.org/10.1200/JCO.2009.26.2493CrossRefPubMed

27.

Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114(11):2273–2279. https://doi.org/10.1182/blood-2009-03-212191CrossRefPubMedPubMedCentral

28.

Li S, Desai P, Lin P, Yin CC, Tang G, Wang XJ, Konoplev SN, Khoury JD, Bueso-Ramos CE, Medeiros LJ (2016) MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology 68(7):1090–1098. https://doi.org/10.1111/his.12884CrossRefPubMed

29.

Huang W, Medeiros LJ, Lin P, Wang W, Tang G, Khoury J, Konoplev S, Yin CC, Xu J, Oki Y, Li S (2018) MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol 31(9):1470–1478. https://doi.org/10.1038/s41379-018-0067-xCrossRefPubMed

30.

Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P (2015) MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 126(22):2466–2474. https://doi.org/10.1182/blood-2015-05-647602CrossRefPubMed

31.

Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow L, Goodlad J, Buxton J, Neat M, Fields P, Wilkins B, Grant JW, Wright P, Ei-Daly H, Follows GA, Roman E, Watkins AJ, Johnson PW, Jack A, Du MQ (2015) The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res 1(3):125–133. https://doi.org/10.1002/cjp2.10CrossRefPubMedPubMedCentral

32.

Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, Ruminy P, Picquenot JM, Tilly H (2007) Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 21(3):515–523. https://doi.org/10.1038/sj.leu.2404529CrossRefPubMed

33.

Otto C, Scholtysik R, Schmitz R, Kreuz M, Becher C, Hummel M, Rosenwald A, Trümper L, Klapper W, Siebert R, Küppers R (2016) Novel IGH and MYC translocation partners in diffuse large B-cell lymphomas. Genes Chromosom Cancer 55(12):932–943. https://doi.org/10.1002/gcc.22391CrossRefPubMed

34.

Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Nørgaard P (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 92(1):42–48. https://doi.org/10.1111/ejh.12212CrossRefPubMed

35.

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Kuppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trumper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network P (2014) Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 99(4):726–735. https://doi.org/10.3324/haematol.2013.091827CrossRefPubMedPubMedCentral

36.

Salaverria I, Siebert R (2011) The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol 29(14):1835–1843. https://doi.org/10.1200/jco.2010.32.8385CrossRefPubMed

37.

Gualco G, Weiss LM, Harrington WJ, Bacchi CE (2009) Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Am J Surg Pathol 33(12):1815–1822. https://doi.org/10.1097/pas.0b013e3181bb9a18CrossRefPubMedPubMedCentral

38.

Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, Kohler CW, Richter J, Pienkowska-Grela B, Adam P, Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, Hummel M, Jaffe ES, Kuppers R, Lefebvre C, Lisfeld J, Loffler M, Macleod RAF, Nagel I, Oschlies I, Rosolowski M, Russell RB, Rymkiewicz G, Schindler D, Schlesner M, Scholtysik R, Schwaenen C, Spang R, Szczepanowski M, Trumper L, Vater I, Wessendorf S, Klapper W, Siebert R (2014) A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 123(8):1187–1198. https://doi.org/10.1182/blood-2013-06-507996CrossRefPubMedPubMedCentral

39.

Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balagué O, Celis V, Verdu-Amoros J, Nadeu F, Sábado C, Ferrández A, Garrido M, García-Bragado F, De La Maya MD, Vagace JM, Panizo CM, Astigarraga I, Andrés M, Jaffe ES, Campo E, Salaverria I (2019) Burkitt-like lymphoma with 11q aberration: a germinal center derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 104(9):1822–1829. https://doi.org/10.3324/haematol.2018.207928CrossRefPubMedPubMedCentral

40.

Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ (2012) Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118(6):1566–1573. https://doi.org/10.1002/cncr.26433CrossRefPubMed

41.

Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, Aoun P, Chan WC, Fu K, Greiner TC, Bierman P, Gregory Bociek R, Vose JM, Armitage JO, Weisenburger DD (2013) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Brit J Haematol 162(1):40–49. https://doi.org/10.1111/bjh.12343CrossRef

42.

Wang XJ, Reddy N, Li S (2013) MYC gene single hit diffuse large B cell lymphoma behaves similarly to MYC/BCL2 double hit lymphoma and needs similar aggressive treatment. Blood 122(21):4313. https://doi.org/10.1182/blood.V122.21.4313.4313CrossRef

43.

Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li SY, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao WQ, Vanslambrouck C, Nabhan C (2016) Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Brit J Haematol 175(4):631–640. https://doi.org/10.1111/bjh.14282CrossRef

44.

Li SY, Weiss VL, Wang XJ, Desai PA, Hu SM, Yin CC, Tang GL, Reddy NM, Medeiros LJ, Lin P (2016) High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis. Am J Surg Pathol 40(2):253–261. https://doi.org/10.1097/Pas.0000000000000542CrossRefPubMed

45.

Pedersen MØ, Gang AO, Clasen-Linde E, Breinholt MF, Knudsen H, Nielsen SL, Poulsen TS, Klausen TW, Høgdall E, Nørgaard P (2019) Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-identifies a subgroup of patients with poor outcome. Eur J Haematol 102(5):395–406. https://doi.org/10.1111/ejh.13219CrossRefPubMed

46.

Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Moller MB, You MJ, McDonnell T, Medeiros LJ, Young KH (2014) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 27(7):958–971. https://doi.org/10.1038/modpathol.2013.214CrossRefPubMed

47.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459. https://doi.org/10.1200/JCO.2011.41.0985CrossRefPubMedPubMedCentral

48.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P (2017) Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol 35(1):24–31. https://doi.org/10.1200/JCO.2016.68.2740CrossRefPubMed

49.

Kluk MJ, Chapuy B, Sinha P, Roy A, Cin PD, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ (2012) Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 7(4):e33813. https://doi.org/10.1371/journal.pone.0033813CrossRefPubMedPubMedCentral

50.

Cook JR, Goldman B, Tubbs RR, Rimsza L, Leblanc M, Stiff P, Fisher R (2014) Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol 38(4):494–501. https://doi.org/10.1097/PAS.0000000000000147CrossRefPubMedPubMedCentral

51.

Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Moller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH (2015) Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 28(12):1555–1573. https://doi.org/10.1038/modpathol.2015.118CrossRefPubMed

52.

Ziepert M, Lazzi S, Santi R, Vergoni F, Granai M, Mancini V, Staiger A, Horn H, Loffler M, Poschel V, Held G, Wulf G, Trumper LH, Schmitz N, Rosenwald A, Sabattini E, Naresh KN, Stein H, Ott G, Leoncini L (2020) A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. Haematologica. https://doi.org/10.3324/haematol.2019.235556

53.

Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Ohshima K, Sone H, Takizawa J (2016) MYC translocation and/or BCL2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci 107(6):853–861. https://doi.org/10.1111/cas.12942CrossRefPubMedPubMedCentral

54.

Sesques P, Johnson NA (2017) Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood 129(3):280–288. https://doi.org/10.1182/blood-2016-02-636316CrossRefPubMed

55.

de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, van Maanen T, Lindauer-van der Werf G, Beeker A, Timmers GJ, Schaar CG, Soesan M, Poddighe PJ, de Jong D, Chamuleau ME (2016) Diffuse large B-cell lymphoma with MYC gene rearrangements: current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature. Eur J Cancer 55:140–146. https://doi.org/10.1016/j.ejca.2015.12.001CrossRefPubMed

56.

Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW (2015) Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 15(6):341–348. https://doi.org/10.1016/j.clml.2014.12.015CrossRefPubMed

57.

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH (2018) MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. Leuk Lymphoma 59(2):505–508. https://doi.org/10.1080/10428194.2017.1339882CrossRefPubMed

58.

Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M, Miura I (2019) Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements. Haematologica 104(7):1417–1421. https://doi.org/10.3324/haematol.2018.204958CrossRefPubMedPubMedCentral

59.

McKeown MR, Bradner JE (2014) Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med 4(10). https://doi.org/10.1101/cshperspect.a014266

60.

Koh CM, Sabo A, Guccione E (2016) Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays 38(3):266–275. https://doi.org/10.1002/bies.201500134CrossRefPubMedPubMedCentral

61.

Abramson JS, Siddiqi T, Palomba ML, Gordon LI, Lunning MA, Arnason JE, Wang M, Forero-Torres A, Albertson T, Dehner C, Garcia J, Li D, Xie B, Maloney DG (2018) High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol 36(5_suppl):120–120. https://doi.org/10.1200/JCO.2018.36.5_suppl.120CrossRef

62.

National Comprehensive Cancer Network (2020) Diffuse large B-cell lymphoma (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 5/20/2020

63.

Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207. https://doi.org/10.1200/jco.2010.30.0368CrossRefPubMed

64.

Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T (2013) Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology 63(6):788–801. https://doi.org/10.1111/his.12223CrossRefPubMed

65.

Hwang HS, Park C-S, Yoon DH, Suh C, Huh J (2014) High concordance of gene expression profiling–correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol 38(8):1046–1057. https://doi.org/10.1097/pas.0000000000000211CrossRefPubMed

66.

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 33(26):2848–2856. https://doi.org/10.1200/jco.2014.60.2383CrossRefPubMedPubMedCentral

67.

Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L (2019) MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. Haematologica 104(1):e25–e28. https://doi.org/10.3324/haematol.2018.195958CrossRefPubMedPubMedCentral

68.

Mahmoud AZ, George TI, Czuchlewski DR, Zhang Q-Y, Wilson CS, Sever CE, Bakhirev AG, Zhang D, Steidler NL, Reichard KK, Kang H, Foucar K, Vasef MA (2015) Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Mod Pathol 28(4):545–551. https://doi.org/10.1038/modpathol.2014.140CrossRefPubMed

69.

Raess PW, Moore SR, Cascio MJ, Dunlap J, Fan G, Gatter K, Olson SB, Braziel RM (2018) MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. Leuk Lymphoma 59(6):1391–1398. https://doi.org/10.1080/10428194.2017.1370547CrossRefPubMed

70.

Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJD, Schuster SJ (2014) ‘Double-hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Brit J Haematol 166(3):369–374. https://doi.org/10.1111/bjh.12901CrossRef

71.

Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, Comerma L, Hernandez S, Calvo X, Salar A, Climent F, Mate JL, Forcada P, Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Dlouhy I, Salaverria I, Martin-Subero JI, Lopez-Guillermo A, Valera A, Campo E, Grup per l'Estudi dels Limfomes de Catalunya i B (2017) LMO2-negative expression predicts the presence of MYC translocations in aggressive B-cell lymphomas. Am J Surg Pathol 41(7):877–886. https://doi.org/10.1097/PAS.0000000000000839CrossRefPubMed

Title: A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas
Authors: Daniel P. Larson
Jess F. Peterson
Grzegorz S. Nowakowski
Ellen D. McPhail
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Fluorescence in Situ Hybridization
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Journal of Hematopathology / Issue 3/2020
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-020-00404-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Prevalence of β-haemoglobinopathies in Eastern India and development of a novel formula for carrier detection

Histopathological and clinical features of nodular lymphocyte-predominant Hodgkin lymphoma and their impact on prognosis: first report from Iran

Mucosal intralymphatic spread in a relapsed diffuse large B cell lymphoma

IgH gene rearrangement by PCR as an adjunct to flow cytometric analysis for the detection of minimal residual disease in patients with B lymphoblastic leukemia

Activation of cytotoxic T cell population and inversion of CD4:CD8 ratio as manifestations of cellular immune response in SARS-COV-2 infection

Pediatric post-transplant lymphoproliferative disorder identified on random gastrointestinal biopsies shows non-mass-forming PTLD with clonal plasma cells: report of 2 cases